SCHEMBL6801787

SCHEMBL6801787

CC(C)Cc1coc(-c2ccccn2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.43
HTT P42858 2/20 0.41
NPC1 O15118 8/20 0.41
KDM4E B2RXH2 7/20 0.41
TP53 P04637 7/20 0.41
SMN1; SMN2 Q16637 7/20 0.41
RAB9A P51151 7/20 0.41
HSD17B10 Q99714 4/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
PKM P14618 6/20 0.38
LMNA P02545 2/20 0.38
CCR1 P32246 2/20 0.38
CCR5 P51681 2/20 0.38
CCR8 P51685 2/20 0.38
POLB P06746 2/20 0.38
METAP1 P53582 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1201329 0.84 RORC (0.33) KDM4EHSD17B10ALDH1A1HPGDTSHR
SCHEMBL8239614 0.83 SMN1; SMN2 (0.44) HTTNPC1KDM4ETP53SMN1; SMN2
SCHEMBL27041761 0.79 KDM4E (0.42) HTTNPC1KDM4ETP53SMN1; SMN2
SCHEMBL9282001 0.78 CYP1A2 (0.43) NPC1KDM4ETP53SMN1; SMN2RAB9A
SCHEMBL13615821 0.78 IDH1 (0.43) KDM4EHSD17B10ALDH1A1HPGDTSHR
SCHEMBL20402654 0.74 KDM4E (0.57) TRPM8HTTNPC1KDM4ETP53
SCHEMBL8239720 0.74 NPC1 (0.47) HTTNPC1KDM4ETP53SMN1; SMN2
SCHEMBL9285629 0.73 HDAC3 (0.33) NPC1SMN1; SMN2RAB9AMETAP1
SCHEMBL28446799 0.73 ALDH1A1 (0.37) NPC1KDM4ESMN1; SMN2RAB9AHSD17B10
SCHEMBL9923084 0.71 EGFR (0.50) TRPM8NPC1KDM4ETP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6730671-B2 ENZYME INHIBITOR TREATING AUTOIMMUNE DISEASES, ALZHEIMER'S DISEASE, ATHEROSCLEROSIS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2004-05-04 US disclosed
US-20030158406-A1 Compounds useful as reversible inhibitors of cathepsin S BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-08-21 US disclosed
US-6608057-B2 Compounds useful as reversible inhibitors of cathepsin S BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-08-19 US disclosed
US-20020091259-A1 Compounds useful as reversible inhibitors of cathepsin S CYWIN CHARLES L (US) 2002-07-11 US disclosed
US-6395897-B1 DRUGS FOR ENZYME INHIBITORS ANTICOAGULANTS AND TREATMENT OF AUTOIMMUNE DISEASE BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2002-05-28 US disclosed
EP-1159273-A1 COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CATHEPSIN S BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2001-12-05 EP disclosed
WO-2000051998-A1 COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CATHEPSIN S BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2000-09-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091259-A1 Compounds useful as reversible inhibitors of cathepsin S CTSS, CTSB, CTSV TRPM8 888/4885HTT 3135/4885NPC1 239/4885
US-20030158406-A1 Compounds useful as reversible inhibitors of cathepsin S CTSS, CTSB, CTSV TRPM8 888/4885HTT 3135/4885NPC1 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.